Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Clinical trial NCT02595866 · COMPLETED

Trial details

NCT number: NCT02595866
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

AIDS-Related Non-Hodgkin Lymphoma Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Hepatocellular Carcinoma HIV Infection Kaposi Sarcoma Locally Advanced Lung Non-Small Cell Carcinoma Locally Advanced Malignant Solid Neoplasm Metastatic Lung Non-Small Cell Carcinoma Metastatic Malignant Solid Neoplasm Metastatic Melanoma Non-Hodgkin Lymphoma

Start date: 2016-04-04
Primary completion: 2023-10-04
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.